AM2454

AM2454 is a preclinical-stage biodegradable implant developed by AMW for the treatment of obesity, diabetes, and cardiovascular diseases associated with metabolic syndrome. The product is designed to provide sustained release of a glucagon-like peptide-1 (GLP-1) receptor agonist over a period of approximately three months. By utilizing AMW's proprietary drug delivery technology, AM2454 aims to improve patient compliance and therapeutic outcomes by reducing the frequency of administration compared to standard daily or weekly GLP-1 injections. The formulation is intended to regulate blood glucose levels and promote weight loss through the continuous agonism of the GLP-1 receptor.